Natera’s Signatera Volumes Surge, Driving 40% Q4 Revenue Growth to $666M
Carillon Eagle Mid Cap Growth Fund cited Natera’s Signatera oncology test volume growth exceeding consensus, prompting a raised revenue growth guidance. Natera reported Q4 2025 revenue of $666 million, up 40% year-over-year, alongside improved gross margins and sustained positive free cash flow.
1. Fund Letter Highlights Signatera Growth
Carillon Eagle Mid Cap Growth Fund identified Natera’s Signatera oncology test as a top contributor in Q4 2025, noting that volumes exceeded consensus estimates and led management to raise its revenue growth guidance.
2. Robust Q4 Revenue Performance
Natera recorded Q4 2025 revenue of $666 million, marking a 40% increase from Q4 2024 driven by strong adoption of its Signatera molecular testing services.
3. Strengthening Profitability Metrics
Gross margins expanded sequentially in the quarter and the company maintained positive free cash flow, reflecting operational leverage from its molecular diagnostics platform.
4. Growing Institutional Ownership
Hedge fund holdings in Natera rose to 74 portfolios at year-end, up from 70 in the prior quarter, indicating increased institutional confidence in its growth prospects.